Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib

Adjuvant cisplatin-based chemotherapy is considered the standard of care for resected stage IB (tumor ≥ 4m)–IIIA non-small cell lung cancer (NSCLC). The ADAURA trial is a randomized placebo-controlled Phase III trial that demonstrated statistically significant improved disease-free survival (DFS) wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Shannon S, Ou, Sai-Hong Ignatius
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057228/
https://www.ncbi.nlm.nih.gov/pubmed/35506019
http://dx.doi.org/10.2147/LCTT.S358902

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057228/
https://www.ncbi.nlm.nih.gov/pubmed/35506019
http://dx.doi.org/10.2147/LCTT.S358902

Ejemplares similares